[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536134":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":11,"centralContacts":31,"locations":37,"responsibleParty":55,"collaborators":11,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":11,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":11,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Calgary","OTHER",[8,14,17,20,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Ringer's lactate 2500 cc IV","EXPERIMENTAL",null,[13],"Other: Intravenous Ringer's lactate",{"label":15,"type":10,"description":11,"interventionNames":16},"Ringer's lactate 2000 cc IV",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Ringer's lactate 1500 cc IV",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Ringer's lactate 1000 cc IV",[13],{"label":24,"type":25,"description":11,"interventionNames":26},"Ringer's lactate 500 cc IV","ACTIVE_COMPARATOR",[13],[28],{"type":6,"name":29,"description":29,"armGroupLabels":30,"otherNames":11},"Intravenous Ringer's lactate",[21,18,15,9,24],[32],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Nauzer Forbes, MD, MSc","CONTACT","403-880-8508","nauzer.forbes@ucalgary.ca",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Peter Lougheed Centre","RECRUITING","Calgary","Alberta","T1Y 6J4","Canada","CA",{"type":47,"coordinates":48},"Point",[49,50],-114.08529,51.05011,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":35,"phoneExt":11,"email":36},"Nauzer Forbes, MD",{"type":56,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100536134","phase-4-short-term-intravenous-fluids-for-prevention-of-post-ercp-pancreatitis-100536134",false,"NCT06260878","Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis","STRIPE","Inclusion Criteria:\n\n1. age 18-75 years (due to higher likelihood of undiagnosed cardiac disease or renal insufficiency in patients \\>75 years of age)\n2. ability to give informed consent\n3. native major papillary anatomy\n4. ability and willingness to obtain bloodwork the day after ERCP\n\nExclusion Criteria:\n\n1. prior ERCP with sphincterotomy and\u002For sphincteroplasty\n2. confirmed or suspected cholangitis or sepsis\n3. confirmed pancreatitis, hyperlipasemia, or hyperamylasemia within the preceding 7 days\n4. NYHA Class II or greater heart failure\n5. active pulmonary edema\n6. myocardial infarction or ischemia within the preceding 3 months\n7. renal insufficiency with CrCl \\\u003C 40 mL\u002Fminute\n8. CPT Class B or C cirrhosis and\u002For end-stage liver disease\n9. room air oxygen saturation \\\u003C90% or requirement of home O2\n10. hypernatremia with Na+ ≥ 150 mEq\u002FL or Na+ \\\u003C130 mEq\u002FL\n11. uncontrolled hypertension or hypotension\n12. pregnant status",true,"ALL","18 Years","75 Years",{"count":69,"type":70},505,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative.",[76],"Post-ERCP Acute Pancreatitis","2026-04-28",{"date":79,"type":80},"2026-04-29","ACTUAL",{"date":82,"type":80},"2024-11-22",{"date":84,"type":70},"2028-12-31",{"name":5,"class":6},1]